To this end, we initially characterised the ability of CAFs to modulate resistance to treatment in HER2-positive breast cancer cell lines, using cellular assays of proliferation, migration, spheroid formation and molecular characterisation of EMT markers. Here, ERBB2 is linked to breast carcinoma.